Skip to content

Study · Not a test of the peptide alone · 1990

1 result

[The usefulness of event-related negativity in demonstrating the therapeutic effects of nootropic drugs using cerebrolysin as an example].

Kofler B, Erhart C, Erhart P, Harrer G

EEG-EMG Zeitschrift fur Elektroenzephalographie, Elektromyographie und verwandte Gebiete1 Sept 1990Cited by 1 (Europe PMC)

PMID2123433 (opens in a new tab)PepBankPUB-02123433
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneRandomized controlled trialActivity measurement

    In geriatric patients with moderate organic brain syndrome, cerebrolysin plus multivitamin infusions significantly increased CNV amplitude versus pretreatment values.

    In plain wordsIn geriatric patients, cerebrolysin plus multivitamin infusions increased CNV amplitude compared with pretreatment values.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCNV amplitude
    Study

    n = 27

    Comparator
    Pretreatment values
    Outcome group
    Brain and neuronal activity · Nervous system and cognition

    Source sentences

    Summary
    After ten Cerebrolysin- plus multi-vitamins-Infusions, the treatment group of 27 patients showed a significant CNV-amplitude increase as compared to pre-treatment values.
    1 context sentence
    Summary · context
    A total of 41 geriatric patients with the diagnosis of moderate organic brain syndrome of different etiology were included in this randomized placebo-controlled double-blind study.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.